OncoMatch/Clinical Trials/NCT07454382
A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma
Is NCT07454382 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Elranatamab-bcmm and Cyclophosphamide for multiple myeloma.
Treatment: Elranatamab-bcmm · Cyclophosphamide — The purpose of this study is to find out whether the combination of elranatamab and cyclophosphamide is an effective treatment for people with relapsed/refractory multiple myeloma (MM) who have risk factors that may affect how well their disease would respond to elranatamab alone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory drug (thalidomide, lenalidomide, pomalidomide)
At least 1 IMiD (thalidomide, lenalidomide or pomalidomide)
Must have received: proteasome inhibitor (bortezomib, carfilzomib, ixazomib)
At least 1 PI (bortezomib, carfilzomib or ixazomib)
Must have received: anti-CD38 monoclonal antibody (daratumumab, isatuximab)
At least 1 anti-CD38 monoclonal antibody (daratumumab or isatuximab)
Cannot have received: CD3 redirecting bispecific or trispecific antibody
Previous treatment with a CD3 redirecting bispecific or trispecific antibody for multiple myeloma
Cannot have received: autologous stem cell transplant
Exception: within 8 weeks prior to enrollment
History of autologous stem cell transplant within 8 weeks prior to enrollment
Cannot have received: allogeneic stem cell transplant
Exception: within 12 weeks prior to enrollment
history of allogeneic stem cell transplant within 12 weeks prior to enrollment
Lab requirements
Blood counts
ANC ≥ 1,000 cells/mm3 (use of G-CSF is permitted if completed at ≥7 days prior to planned start of study treatment); Platelets ≥ 25,000 cells/mm3 (transfusion support is permitted); Hemoglobin ≥ 8 g/dl (transfusion support is permitted)
Kidney function
Creatinine clearance (CrCL) of ≥15 mL/min by the CKD-EPI formula, Cockcroft-Gault formula, or with direct measurement
Liver function
Total bilirubin ≤ 1.5 x institutional ULN (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled); AST and ALT ≤3 x institutional ULN
Cardiac function
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function
Adequate hematologic function... Adequate renal function... Adequate hepatic function... Adequate cardiac function...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (All Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (All Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (All Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (All Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07454382 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CD3 redirecting bispecific or trispecific antibody, autologous stem cell transplant, allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages